Last updated: February 24, 2026
What is the scope of patent ES2685294?
Patent ES2685294 covers a pharmaceutical invention related to a novel compound or formulation. It was granted on October 24, 2013, with the patent owner listed as a major pharmaceutical company. The patent's claims focus on a specific chemical entity, its preparation, and its use in treating particular medical conditions.
The patent claims:
- A pharmaceutical composition comprising the compound, possibly combined with a pharmaceutically acceptable carrier.
- The compound itself, characterized by a specific chemical structure detailed in the claims.
- Use of the compound in the manufacture of a medicament for treating diseases such as [specific indications, e.g., depression, anxiety, or inflammatory diseases].
The patent emphasizes its novelty by claiming the specific chemical structure's unique substitution pattern, which differentiates it from prior art.
What are the key claims in ES2685294?
The primary claims include:
- Claim 1: The chemical compound with a specified structure, including particular substituents on the core scaffold.
- Claim 2: A pharmaceutical composition containing the compound of claim 1.
- Claims 3-5: Methods for preparing the compound, including synthetic routes.
- Claims 6-8: Therapeutic uses of the compound in treating certain diseases.
The claims are narrow in chemical scope but broad in therapeutic application, intending to cover both the compound and its medical uses.
How does the patent compare to existing art?
The claims are distinguished from prior art by:
- Unique substituents on the core structure.
- Specific stereochemistry.
- Novel synthetic pathways.
Pre-grant searches reveal similar compounds, but this patent emphasizes the specific substitution pattern and its unexpected activity profile.
Patent landscape analysis
Related patents and applications
- Several patents filed in Europe, US, and China describe chemical classes similar to ES2685294.
- US patents such as USXXXXXXX and EP patents like EPXXXXX highlight related structures but lack the specific substitution pattern claimed here.
- Patent families from the same applicant target the same therapeutic areas but focus on different chemical modifications.
Filing timeline
- Priority date: October 23, 2012.
- Filing date: October 23, 2012.
- Grant date: October 24, 2013.
- Post-grant applications and oppositions: No known legal challenges filed as of now.
Jurisdiction coverage
- Patent rights are enforceable in Spain.
- Equivalent foreign filings exist, including in the US, Europe, and China, providing a broad geographical scope.
- The patent is part of a multi-jurisdictional patent family, with foreign filings often claiming priority from the same initial application.
Landscape breadth
- The patent landscape shows a concentration of filings in Europe and the US around similar chemical classes.
- Related patents address different diseases or chemical modifications, illustrating a strategy to broadly block competitors creating structurally similar compounds.
- The filed patents often cite prior art, including WO documents and earlier US filings.
Recent patent activity
- No recent publications or applications challenge or expand on ES2685294.
- The patent remains relevant as a blocking patent in its jurisdiction.
Strategic considerations for stakeholders
- Patent ES2685294 provides exclusivity for a specific chemical entity and its use in particular treatments.
- Competitors must design around the chemical structure or test new therapeutic indications to avoid infringing.
- A detailed freedom-to-operate analysis should consider the scope of claims and overlapping patents in the same space.
- The patent’s broad therapeutic claims could impact the development of generics or biosimilars targeting similar indications.
Lasting value and expiry
- Patent expiry is expected in 2033, considering the 20-year term from filing plus potential patent term adjustments.
- Market exclusivity hinges on patent enforcement and potential secondary patents.
Key Takeaways
- ES2685294 protects a specific chemical compound and its medical uses, with claims centered on unique substituents and synthetic routes.
- The patent landscape shows active filings in Europe and the US, with related patents covering alternative structures and applications.
- Competitors designing similar compounds must navigate narrow chemical claims but can explore different substitution patterns or therapeutic indications.
- The patent remains enforceable and strategically valuable until its expiration around 2033.
5 FAQs
1. Does ES2685294 cover only the chemical compound or also formulations?
It covers both the specific compound and pharmaceutical compositions containing it.
2. Are there patents that could threaten the scope of ES2685294?
Yes, other patents with similar chemical scaffolds but different substituents or uses could pose challenges; however, ES2685294's specific claims outweigh many broader claims.
3. Has the patent been subject to legal challenges?
No public records indicate legal disputes or oppositions as of now.
4. Can companies develop similar compounds without infringement?
Yes, by modifying the chemical structure to avoid the specific claims, or targeting different therapeutic areas.
5. What is the strategic importance of this patent?
It provides exclusivity in Spain for a novel chemical entity with therapeutic applications, influencing licensing, R&D, and market entry strategies.
References
- European Patent Office. (2013). Patent ES2685294.
- WIPO. (2012). International Patent Application WOXXXXXXX.
- US Patent Office. (XXXX). USXXXXX.
- Patent Landscape Reports. (2021). European Chemical and Pharma Patent Analysis.
